YM BioSciences gets go-ahead for phase II brain cancer drug trial

July 2007
PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p18
Market Research Report
The article reports that YM BioSciences Inc. has obtained a clearance from Health Canada to initiate its phase II trial for Nimotuzumab, an experimental drug used to treat patients with recurrent diffuse intrinsic pontine glioma. According to the author, the company is given 18 months to assess the potential of Nimotuzumab in treating brain cancer. President David Allan states that the firm remains optimistic that the trial will provide favorable outcomes.


Related Articles

  • Finding Nimo's Path Forward: Cuban Bid by YM Biosciences. Osborne, Randy // BioWorld Insight;8/17/2009, Vol. 17 Issue 33, p1 

    In this article, the author discusses the effort of YM Bioscience Inc. to win U.S. acceptance for a potential cancer blockbuster that originated in Cuba. According to company president David Allan, their effort has nothing to do with politics. It states that if the company fails to persuade the...

  • Brain Cancer Update.  // PharmaWatch: Cancer;Apr2005, Vol. 4 Issue 4, p18 

    The article presents update on several clinical trials related to brain cancer treatment. Oncolytics will begin the phase I/II clinical trial to investigate the use of Reolysic to treat patients with brain cancer in the U.S. Myriad Genetics Inc. announced its plan to begin a second phase I...

  • ASCO ROUNDUP.  // BioWorld Today;6/4/2008, Vol. 19 Issue 108, p7 

    The article reports on the results of YM BioSciences Inc.'s preliminary Phase III study of its cancer drug nimotuzumab. Results presented a median overall survival of 9.7 months in children and adolescents that were newly diagnosed with diffuse intrinsic pontine gliomas.

  • FDA Puts Hold on Phase II AeroLEF Study.  // Bioworld Week;1/21/2008, Vol. 16 Issue 3, p5 

    The article reports that shares of YM Biosciences Inc. in Mississauga, Ontario fell 12 percent on news that the U.S. Food and Drug Administration placed a clinical hold on a Phase II study of AeroLEF in acute pain. The agency requested additional safety information, specifically data from...

  • YM BioSciences gets approval for Canadian colorectal cancer trial.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p12 

    The article reports on the approval of YM BioSciences Inc.'s clinical trial from Health Canada. YM BioSciences will initiate its planned phase II trial investigating nimotuzumab in colorectal cancer patients who have failed previous irinotecan-containing regimens. The single-arm trial will...

  • YM Could Bring in Up to $7.75M in Controlled Equity Financing. Hollingsworth, Catherine // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of YM Biosciences Inc. to sell up 7.75 million shares in a financing known as a controlled equity offering in 2010. Chief Executive Officer (CEO) David Allan said YM Biosciences may be the first Canadian biotechnology company to initiate such a financing. The...

  • R&D Update.  // PharmaWatch: CNS;Aug2007, Vol. 6 Issue 8, p16 

    The article offers news briefs related to pharmaceutical industries which develop pain drugs. Genzyme Corp. states that its osteoarthritis pain drug hylastan has failed in its clinical trial. Labopharm Inc. mentions that the U.S. Food and Drug Administration requires them to conduct another...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Oct2006, Vol. 5 Issue 10, p2 

    This article presents several news briefs related to biotechnology. ExonHit Therapeutics has discovered a new map for the human genome which helped in identifying all the splicing events in 22,000 human genes. A safety monitoring board has allowed YM BioSciences Inc. to conduct a trial of its...

  • YM BioSciences cancer vaccine demonstrates potential in preliminary data.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p28 

    Reports that preliminary results from YM BioSciences' safety and immunogenicity trial of Norelin vaccine for the treatment of hormone dependant prostate cancer have shown that the vaccine was well tolerated with no major adverse events reported. Design of the study to evaluate the vaccine and to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics